1544 / 1544
Conclusions
• IMRT is now an accepted standard for LA NSCLC
radiotherapy
• Specific dose-constraints on low doses should be
adopted
• Ongoing trials will clarify us the role of PET-guided hypo-
fractionated boost and the best chemotherapy
combination
• New drugs will hopefully amplify the benefit of the
combined modality approach